Skip to main content
Erschienen in: Digestive Diseases and Sciences 7/2022

30.05.2022 | DDS Citation Classics

The GI Effects of GLP-1 – The Genesis of Longstanding Progress

verfasst von: Jonathan D. Kaunitz

Erschienen in: Digestive Diseases and Sciences | Ausgabe 7/2022

Einloggen, um Zugang zu erhalten

Excerpt

Behind every major discovery is a backstory of scientific advances that created the technology and knowledge that provided the substrate on which creativity, innovation, and persistence generated a paradigm shift that radically changes the approach to a disease entity. Such is the case for the discovery of the glucagon-like peptides (GLP), whose stable analogs have immeasurably contributed to the therapy of metabolic diseases and intestinal failure [13]. …
Literatur
1.
Zurück zum Zitat Sandoval DA, D’Alessio DA. Physiology of proglucagon peptides: role of glucagon and GLP-1 in health and disease. Physiol Rev 2015;95:513–548.CrossRef Sandoval DA, D’Alessio DA. Physiology of proglucagon peptides: role of glucagon and GLP-1 in health and disease. Physiol Rev 2015;95:513–548.CrossRef
2.
Zurück zum Zitat Blumenstein I. GLP-2 Analogues as First Specific Treatment of Intestinal Failure. Visc Med 2019;35:320–323.CrossRef Blumenstein I. GLP-2 Analogues as First Specific Treatment of Intestinal Failure. Visc Med 2019;35:320–323.CrossRef
3.
Zurück zum Zitat Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 2012;8:728–742.CrossRef Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 2012;8:728–742.CrossRef
5.
Zurück zum Zitat Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ. Truncated GLP-1 (proglucagon 78–107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 1993;38:665–673.CrossRef Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ. Truncated GLP-1 (proglucagon 78–107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 1993;38:665–673.CrossRef
6.
Zurück zum Zitat Rehfeld JF, Heding LG, Holst JJ. Increased gut glucagon release as pathogenetic factor in reactive hypoglycaemia? Lancet 1973;1:116–118.CrossRef Rehfeld JF, Heding LG, Holst JJ. Increased gut glucagon release as pathogenetic factor in reactive hypoglycaemia? Lancet 1973;1:116–118.CrossRef
7.
Zurück zum Zitat Holst JJ, Orskov C, Nielsen OV, Schwartz TW. Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut. FEBS Lett 1987;211:169–174.CrossRef Holst JJ, Orskov C, Nielsen OV, Schwartz TW. Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut. FEBS Lett 1987;211:169–174.CrossRef
8.
Zurück zum Zitat Rehfeld JF. The origin and understanding of the incretin concept. Front Endocrinol (Lausanne) 2018;9:387.CrossRef Rehfeld JF. The origin and understanding of the incretin concept. Front Endocrinol (Lausanne) 2018;9:387.CrossRef
9.
Zurück zum Zitat Bayliss WM, Starling EH. The mechanism of pancreatic secretion. J Physiol 1902;28:325–353.CrossRef Bayliss WM, Starling EH. The mechanism of pancreatic secretion. J Physiol 1902;28:325–353.CrossRef
10.
Zurück zum Zitat La Barre J. Sur les possibilités d’un traitement du diabète par l’incrètine. Bull Acad Royal Med Belg 1932;12:620–634. La Barre J. Sur les possibilités d’un traitement du diabète par l’incrètine. Bull Acad Royal Med Belg 1932;12:620–634.
11.
Zurück zum Zitat Yalow RS, Berson SA. Immunoassay of endogenous plasma insulin in man. J Clin Invest 1960;39:1157–1175.CrossRef Yalow RS, Berson SA. Immunoassay of endogenous plasma insulin in man. J Clin Invest 1960;39:1157–1175.CrossRef
12.
Zurück zum Zitat Edman P. Method for determination of amino acid sequence in peptides. Acta Chemica Scand. 1950;4:283–293.CrossRef Edman P. Method for determination of amino acid sequence in peptides. Acta Chemica Scand. 1950;4:283–293.CrossRef
13.
Zurück zum Zitat Edman P. A method for the determination of amino acid sequence in peptides. Arch Biochem 1949;22:475.PubMed Edman P. A method for the determination of amino acid sequence in peptides. Arch Biochem 1949;22:475.PubMed
14.
Zurück zum Zitat Sanger F, Tuppy H. The amino-acid sequence in the phenylalanyl chain of insulin. 2. The investigation of peptides from enzymic hydrolysates. Biochem J 1951;49:481–490.CrossRef Sanger F, Tuppy H. The amino-acid sequence in the phenylalanyl chain of insulin. 2. The investigation of peptides from enzymic hydrolysates. Biochem J 1951;49:481–490.CrossRef
15.
Zurück zum Zitat Sanger F, Tuppy H. The amino-acid sequence in the phenylalanyl chain of insulin. I. The identification of lower peptides from partial hydrolysates. Biochem J 1951;49:463–481.CrossRef Sanger F, Tuppy H. The amino-acid sequence in the phenylalanyl chain of insulin. I. The identification of lower peptides from partial hydrolysates. Biochem J 1951;49:463–481.CrossRef
Metadaten
Titel
The GI Effects of GLP-1 – The Genesis of Longstanding Progress
verfasst von
Jonathan D. Kaunitz
Publikationsdatum
30.05.2022
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 7/2022
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-022-07520-w

Weitere Artikel der Ausgabe 7/2022

Digestive Diseases and Sciences 7/2022 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.